The prognostic role of the adiponectin levels in atrial fibrillation

European Journal of Clinical Investigation

Volumn 43, Issue 2, 2013, Pages 168-173

  Hernández Romero, Diana ^a   Jover, Eva ^a   Marín, Francisco ^a   Vilchez, Juan A ^a   Manzano Fernandez, Sergio ^a   Romera, Marta ^b   Vicente, Vicente ^b   Valdés, Mariano ^a   Lip, Gregory Y H ^c   Roldán, Vanessa ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b HOSPITAL MORALES MESEGUER   (Spain)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Adiponectin; Atherosclerosis; Atrial fibrillation; Oral anticoagulant treatment; Thrombosis

Indexed keywords

ACENOCOUMAROL; ADIPONECTIN;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; THROMBOEMBOLISM;

ADIPONECTIN; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PROGNOSIS; RISK FACTORS; ROC CURVE; SEX FACTORS;

EID: 84872596861     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12028     Document Type: Article

References (26)

1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82(Suppl):2N-9N.
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silberhatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
4. Jover E, Roldán V, Gallego P, Hernández-Romero D, Valdés M, Vicente V et al. Predictive value of the CHA(2)DS(2)-VASc Score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev Esp Cardiol 2012;65:627-33.
5. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
6. Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against mi in atrial fibrillation patients? Am J Med 2010;123:785-9.
7. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
8. Empana JP. Adiponectin isoforms and cardiovascular disease: the epidemiological evidence has just begun. Eur Heart J 2008;29:1221-3.
9. Hirose H, Yamamoto Y, Seino-Yoshihara Y, Kawabe H, Saito I. Serum high-molecular-weight adiponectin as a marker for the evaluation and care of subjects with metabolic syndrome and related disorders. J Atheroscler Thromb 2010;17:1201-11.
10. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-49.
11. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999;100:2473-6.
12. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.
13. Boyne MS, Bennett NR, Cooper RS, Royal-Thomas TY, Bennett FI, Luke A et al. Sex-differences in adiponectin levels and body fat distribution: longitudinal observations in Afro-Jamaicans. Diabetes Res Clin Pract 2010;90:e33-6.
14. Saltevo J, Kautiainen H, Vanhala M. Gender differences in adiponectin and low-grade inflammation among individuals with normal glucose tolerance, prediabetes, and type 2 diabetes. Gender Med 2009;6:463-70.
15. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002;51:2734-41.
16. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82:29-39.
17. Jover E, Hernández-Romero D, Hurtado JA, Romero-Aniorte AI, Casas T, Valdés M. Serum adiponectin level as a biomarker of coronary artery calcification and severe coronary lesions. Rev Esp Cardiol 2012;65:1060-1.
18. Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011;57:2496-504.
19. Pencina MJ, D'Agostino RB, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
20. Qasim A, Metha NN, Tadesse MG, Wolfe ML, Rhodes T, Girman C et al. Adipokines, insulin resistance, and coronary artery calcification. J Am Coll Cardiol 2008;52:231-6.
21. Son B-K, Akishita M, Iijima J, Zozaki K, Maemura K, Eto M et al. Adiponectin antagonizes stimulatory effect of tumor necrosis factor-alpha on vascular smooth muscle cell calcification: regulation of growth arrest-specific gene 6-mediated survival pathway by adenosine 5′-monophosphate-activated protein kinase. Endocrinology 2008;149:1646-11653.
22. Aprahamian TR, Sam F. Adiponectin in cardiovascular inflammation and obesity. Int J Inflam 2011; in press. doi: 10.4061/2011/376909.
23. Lindberg S, Pedersen SH, Møgelvang R, Bjerre M, Frystyk J, Flyvbjerg A et al. Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2012;109:492-6.
24. Shimano M, Shibata R, Tsuji Y, Kamiya H, Uchikawa T, Harata S et al. Circulating adiponectin levels in patients with atrial fibrillation. Circ J 2008;72:1120-4.
25. Assar O. Low adiponectin level may contribute to higher incidence of postcardiac surgery atrial fibrillation in obese patients. Ann Thorac Surg 2012;93:1762-3.
26. Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 2007;334:786.